Effect of calcitriol combined with irbesartan on renal interstitial fibrosis in patients with early type 2 diabetic nephropathy
Objective:To explore the effect of calcitriol combined with irbesartan in the treatment of early type 2 diabetes nephropathy.Methods:From January 2023 to December 2023,80 patients with early type 2 diabetes nephropathy admitted to our hospital were randomly divided into two groups according to the random number table,with 40 patients in each group.The control group was treated with 150 mg of irbesartan orally,while the observation group was treated with 0.25 μg of calcitriol orally combined with Irbesartan 150 mg for treatment.After 2 months of treatment,the 2-hour postprandial blood glucose(2hPBG),fasting blood glucose(FBG),and glycated hemoglobin(HbA1c)were measured using a blood glucose analyzer.The levels of vascular endothelial growth factor(VEGF),serum homocysteine(Hey),and transforming growth factor(TGF-β1)were measured by the enzyme-linked immunosorbent assay.The treatment effect of patients and the incidence of adverse events were recorded.Results:The therapeutic effect of the observation group was significantly higher than that of the control group(P<0.05).The levels of Hcy,VEGF,and TGF-β1 in the observation group were significantly lower than those in the control group(P<0.05).The levels of FBG,2hPBG,and HbA1c in the observation group were significantly lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group(P>0.05).Conclusion:The combination of calcitriol and irbesartan can improve renal interstitial fibrosis in patients with good safety.
万方数据
维普
